Inflammation in peritoneal dialysis;Inflammation en dialyse péritonéale

Nephrologie

Volumn 24, Issue 7, 2003, Pages 367-370

  Ryckelynck, Jean Philippe ^a,b   Lobbedez, Th ^a   Pujo, M ^a   El Haggan, W ^a   Hurault De Ligny, B ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b CHU Clemenceau   (France)

Author keywords

Biocompatibility; Inflammation; Peritoneal dialysis; Peritoneal dialysis solution

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIALYSIS FLUID; GLUCOSE DEGRADATION PRODUCT; PLASTICIZER;

ANTIBIOTIC RESISTANCE; BIOCOMPATIBILITY; CATHETER; CHRONIC INFLAMMATION; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; INSTRUMENT STERILIZATION; MALNUTRITION; MORTALITY; PERITONEAL DIALYSIS; PERITONITIS; PH;

BIOLOGICAL MARKERS; CATHETERS, INDWELLING; DIALYSIS SOLUTIONS; HUMANS; INFLAMMATION; PERITONEAL DIALYSIS; PERITONITIS; PLASTICIZERS;

EID: 0344444808     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences and Therapy. Sem Dial 2002; 15: 329-37.
2. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol Transplant 2002; 17 (Suppl. 8): 33-8.
3. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frendsdorff A, Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1992; 42: 663-7.
4. Van Riemsdijk-Van Overbeeke IC, Baan CC, Hesse CJ. TNF-α: mRNA plasma protein levels and soluble receptors in patients with chronic haemodialysis, on CAPD and with end-stage renal failure. Clin Nephrol 2000; 53: 115-23.
5. Noh H, Lee SW, Kang SW, Shin SK, Choi KU, Lee HY, Dan DS. Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 1998; 18: 387-94.
6. Pecoits-Filho R, Araujo MRT, Lindholm B, Stenvinkel P, Abensur H, Romao JE, Marcondes M, Freiria de Oliveira AH, Noronka IL. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17: 1480-6.
7. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B. Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation. Kidney Int 1996; 49: 506-11.
8. Zemel D, Ten Berge RJ, Struijk DG, Bloemena E, Koomen C, Krediet R. Interleukin-6 in CAPD patients without peritonitis; relationship to the intrinsic permeability of the peritoneal membrane. Clin Nephrol 1992; 37: 97-103.
9. Lai KN, Lai KB, Lam CW, Chan T, LLF, Leung J. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35: 644-52.
10. Ducloux D, Bressson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62: 1417-22.
11. Verger C, Brunschvicg O, Le Charpentier Y, Lavergne A, Vantelon J. Structural and ultrastructural peritoneal membrane changes and permeability alterations during continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1981; 18:199-205.
12. Di Paolo N, Sacchi G, De Mia M, Gaggiotti E, Capotondo L, Rossi P, Bernini M, Pucci AM, Ibba L, Sabatelli P, Alessandrini C. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron 1986; 44: 204-11.
13. Fracasso A, Coli U, Landini S, Morachiello P, Righetto F, Scanferla F, Genchi R, Bazzato G. Peritoneal sclerosis. Role of plasticizers. ASAIO Trans 1987; 33: 676-82.
14. Mettang T, Thomas S, Kiefer T, Fischer FP, Kuhlmann U, Wodarz R. The fate of leached di (2-ethyl-hexyl) phtalate in patients undergoing CAPD treatment. Perit Dial Int 1996; 16: 58-62.
15. Fischer FP, Machleidt C, Rettenmeier AW, Kuhlmann U, Mettang T. Plasticizers and inhibition of leukocyte function in vitro. Perit Dial Int 1998; 18: 620-5.
16. Passlick-Deetjen J, Gauly A, Marzell B. Utilisation des plastifiants dans le traitement par dialyse. BDP 1997; 7: 90-102.
17. Dasgupta MK, Costerton JW. Signifiance of biofilm-adherent bacterial microcolonies on Tenckhoff catheters of CAPD patients. Blood Purif 1989; 7: 144-55.
18. Dasgupta MK. Biofilm and infection in dialysis patients. Sem Dial 2002; 15: 338-46.
19. Worland MA, Radabaugh, Mueller BA. Intraperitoneal thrombolytic therapy for peritoneal dialysis associated peritonitis. Ann Pharmacother 1998; 32: 1216-20.
20. Davies SJ, Bryan J, Phillips L, Russel GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506.
21. Selgas R, Paiva A, Bajo MA, Cirugeda A, Aguilera A, Diaz C. Consequences of peritonitis episodes apparing late during peritoneal dialysis (PD) in patients able to continue PD. Adv Perit Dial 1998; 14: 168-72.
22. Topley N, Williams JD. Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int 1994; 46 (Suppl. 48): S71-8.
23. Yang WS, Kim BS, Lee SK, Park JS, Kim SB. Interleukin-1b stimulates the production of extracellular matrix in cultured human peritoneal mesothelial cells. Perit Dial Int 1999; 19: 211-20.
24. Williams J, Craigh K, Topley N, Von Ruhland, Fallon M, Newma G, Mackenzie R, Williams G. Morphologic changes in peritoneal membrane of patients with renal disease. JASN 2002; 13: 470-9.
25. Di Paolo N, Garosi G, Petrini G, Traversani L, Rossi P. Peritoneal dialysis solution biocompatibility testing in animals. Perit Dial Int 1945; 15 (Suppl 7): S61-70.
26. Williams J. Biocompatibility in peritoneal dialysis: Definitions and mechanisms. Perit Dial Int 1995; 15 (Suppl. 7): S5-8.
27. Wang T, Yong G, Ye R, Li S, Li H, Chen Y. Effect of glucose on TGF β1 expression in peritoneal mesothelial cells. Adv Perit Dial 1995; 11: 7-10.
28. Kang D, Hong Y, Lim H, Choi J, Han D, Yoon K. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor β1 of human peritoneal mesothelial cells: Effect of cytokine costimulation. Perit Dial Int 1999; 19: 221-30.
29. Krediet R, Zweers M, Van der Wal A, Struijk D. Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000: 20 (Suppl. 2): S19-25.
30. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999; 14: 1541-9.
31. Passlick-Deetjen J, Lage C. Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system. Perit Dial Int 2000; 20 (Suppl. 2): S42-7.
32. Cooker L, Luneburg P, Holmes C, Jones S, Topley N. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001; 21 (Suppl. 3): S102-7.
33. Chung S, Stenvinkel P, Bergström J, Lindolm B. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve ? Perit Dial Int 2000; 20 (Suppl 5): S57-67.
34. Devuyst O. New insights in the molecular mechanisms regulating peritoneal permeability. Nephrol Dial Transplant 2002; 17: 548-51.
35. e 2002; 30-6.